All articles by Sean Rai-Roche

• 

  Blueprint’s Ayvakit expected to take Novartis’ Rydapt crown in advanced systemic mastocytosis but off-label use in indolent unlikely

  Blueprint Medicines’ Ayvakit (avapritinib) is likely to displace its competitor, Novartis’ (SIX:NOVN) Rydapt (midostaurin), in advanced systemic mastocytosis (AdSM), experts…

• 

  Blueprint’s Phase II PIONEER trial of Ayvakit in systemic mastocytosis recruiting speedily, with few barriers to entry, sources say

  Blueprint Medicines’ Phase II PIONEER trial of Ayvakit (avapritinib) in indolent systemic mastocytosis (ISM) is recruiting briskly, investigators and a…

• 

  LoA Update: Amgen’s Nplate in aplastic anemia soars 11 points in FDA likelihood of approval after posting strong trial results

  The FDA Likelihood of Approval (LoA) for Amgen’s Nplate (romiplostim) in aplastic anaemia jumped 11 points as of 22 April, according…

• 

  Keros’ Phase II KER-050 to treat anaemia in myelodysplastic syndrome has potential to exceed low transfusion independence benchmark

  Keros Therapeutics’ KER-050 to treat anaemia in myelodysplastic syndrome (MDS) patients needs 30% of Phase II part 2 trial participants to…

• 

  Omeros’ narsoplimab to replace Alexion’s Soliris as go-to stem cell-associated TMA therapy, with broad clinical utility to lead to strong market traction, say experts

  High mortality and poor existing options result in widespread uptake Soliris price point and some payer pushback make replacement ideal…